Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
Source: SeekingAlpha
2025-12-17 19:59:03 ET
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy December 17, 2025 1:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
Capricor Therapeutics Inc.
NASDAQ: CAPR
CAPR Trading
5.22% G/L:
$26.59 Last:
763,287 Volume:
$25.41 Open:
CAPR Latest News
February 24, 2026 09:00:00 am
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
January 20, 2026 09:15:00 am
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
CAPR Stock Data
$1,278,443,622
46,286,693
0.54%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
